Quest Diagnostics Inc vs Occidental Petroleum Corporation — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Occidental Petroleum Corporation trades at $60.05 (market cap $58.19B). The key difference: Occidental Petroleum Corporation is far larger — about 2.3× Quest Diagnostics Inc's market cap, and Occidental Petroleum Corporation pays the higher dividend (1.92%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Occidental Petroleum Corporation for 92 Days on average.
| DGX | OXY | |
|---|---|---|
Market Cap | $25.06B | $58.19B |
Volume | 927,361 | 7,092,290 |
Sector | Health | Energy |
52-Week High | $247.45 | $66.24 |
52-Week Low | $173.49 | $38.92 |
Typical Hold Time | 56 Days | 92 Days |
Enterprise Value | $30.82B | $76.95B |
Dividend Yield | 1.52% | 1.92% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Occidental Petroleum (OXY) trades at $58.21, down 0.21% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with a 30.32% net income margin and 21.46% ROE, while valuation metrics appear reasonable with a P/E of 17.17 and EV/EBITDA of 5.42. Recent earnings have consistently beaten expectations, and the company maintains a solid balance sheet with $2.13 billion in cash. Analyst consensus is bullish with a $71.40 price target, and the upcoming Q3 2026 earnings report on November 9 is a key catalyst.
OXY presents a compelling investment case with strong fundamentals, reasonable valuation, and positive analyst sentiment. The primary opportunities include continued earnings outperformance, debt reduction progress, and carbon management initiatives. Key risks include oil price volatility, declining revenue trends from $36.6B in 2022 to $21.6B in 2025, and execution challenges in the competitive energy sector. The stock offers upside potential to analyst targets but remains sensitive to commodity price movements.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →